Do analysts rate SVA or IMNM?

Immunome has a consensus target price of $33.17, indicating a potential upside of 44.42%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immunome 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.86

Which has higher valuation & earnings, SVA or IMNM?

Sinovac Biotech has higher revenue and earnings than Immunome. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Immunome $6.94M 374.75 -$212.39M -$2.38 N/A

Is SVA or IMNM more profitable?

Sinovac Biotech's return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Immunome N/A -51.15% -47.32%

Do analysts recommend SVA or TRVI?

Trevi Therapeutics has a consensus target price of $24.91, indicating a potential upside of 40.17%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, SVA or TRVI?

Trevi Therapeutics has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is SVA or TRVI more profitable?

Sinovac Biotech's return on equity of 0.00% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Trevi Therapeutics N/A -24.53% -23.37%

Do analysts rate TARS or SVA?

Tarsus Pharmaceuticals currently has a consensus target price of $90.50, suggesting a potential upside of 56.25%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, TARS or SVA?

Sinovac Biotech has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tarsus Pharmaceuticals $451.36M 5.52 -$66.42M -$1.14 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Do analysts prefer SVA or NRIX?

Nurix Therapeutics has a consensus target price of $34.00, suggesting a potential upside of 45.50%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nurix Therapeutics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has higher earnings & valuation, SVA or NRIX?

Sinovac Biotech has higher revenue and earnings than Nurix Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Nurix Therapeutics $83.98M 28.88 -$264.46M -$3.45 N/A

Which has better valuation and earnings, AGIO or SVA?

Sinovac Biotech has higher revenue and earnings than Agios Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agios Pharmaceuticals $66.05M 31.39 -$412.78M -$7.25 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 07/28/2026

Compare

SVA vs. IMNM, TRVI, TARS, NRIX, and AGIO

Should you buy Sinovac Biotech stock or one of its competitors? MarketBeat compares Sinovac Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sinovac Biotech include Immunome (IMNM), Trevi Therapeutics (TRVI), Tarsus Pharmaceuticals (TARS), Nurix Therapeutics (NRIX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "med - biomed/gene" industry.

How does Sinovac Biotech compare to Immunome?

Sinovac Biotech (NASDAQ:SVA) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Immunome had 12 more articles in the media than Sinovac Biotech. MarketBeat recorded 13 mentions for Immunome and 1 mentions for Sinovac Biotech. Immunome's average media sentiment score of 1.08 beat Sinovac Biotech's score of 0.94 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Positive
Immunome	Positive

44.6% of Immunome shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunome has a consensus target price of $33.17, indicating a potential upside of 44.42%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Sinovac Biotech has higher revenue and earnings than Immunome.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Immunome	$6.94M	374.75	-$212.39M	-$2.38	N/A

Sinovac Biotech's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Immunome	N/A	-51.15%	-47.32%

Sinovac Biotech has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

Summary

Immunome beats Sinovac Biotech on 8 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Trevi Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Sinovac Biotech's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Trevi Therapeutics	N/A	-24.53%	-23.37%

95.8% of Trevi Therapeutics shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Trevi Therapeutics has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Sinovac Biotech has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

In the previous week, Trevi Therapeutics had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 9 mentions for Trevi Therapeutics and 1 mentions for Sinovac Biotech. Trevi Therapeutics' average media sentiment score of 1.02 beat Sinovac Biotech's score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Positive
Trevi Therapeutics	Positive

Trevi Therapeutics has a consensus target price of $24.91, indicating a potential upside of 40.17%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Trevi Therapeutics beats Sinovac Biotech on 10 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Sinovac Biotech has lower revenue, but higher earnings than Tarsus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	5.52	-$66.42M	-$1.14	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Sinovac Biotech has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Sinovac Biotech's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, Tarsus Pharmaceuticals had 6 more articles in the media than Sinovac Biotech. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 1 mentions for Sinovac Biotech. Tarsus Pharmaceuticals' average media sentiment score of 1.05 beat Sinovac Biotech's score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Sinovac Biotech	Positive

Tarsus Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus target price of $90.50, suggesting a potential upside of 56.25%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Sinovac Biotech on 9 of the 15 factors compared between the two stocks.

How does Sinovac Biotech compare to Nurix Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Sinovac Biotech has higher revenue and earnings than Nurix Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Nurix Therapeutics	$83.98M	28.88	-$264.46M	-$3.45	N/A

In the previous week, Nurix Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Nurix Therapeutics and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.94 beat Nurix Therapeutics' score of 0.56 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Sinovac Biotech	Positive
Nurix Therapeutics	Positive

Sinovac Biotech has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Nurix Therapeutics has a consensus target price of $34.00, suggesting a potential upside of 45.50%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Sinovac Biotech has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Sinovac Biotech's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Summary

Sinovac Biotech and Nurix Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Sinovac Biotech has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Sinovac Biotech's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Sinovac Biotech. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.94 beat Agios Pharmaceuticals' score of 0.34 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Agios Pharmaceuticals	Neutral
Sinovac Biotech	Positive

Agios Pharmaceuticals presently has a consensus target price of $40.00, suggesting a potential upside of 14.74%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Agios Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Sinovac Biotech has higher revenue and earnings than Agios Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$66.05M	31.39	-$412.78M	-$7.25	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Summary

Sinovac Biotech beats Agios Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$644.67M	$3.72B	$7.06B	$12.00B
Dividend Yield	N/A	2.17%	2.66%	8.55%
P/E Ratio	N/A	21.94	27.34	23.55
Price / Sales	1.67	295.13	578.45	106.50
Price / Cash	11.89	153.52	49.60	59.05
Price / Book	0.07	7.85	10.00	6.00
Net Income	-$59.68M	$23.81M	$3.60B	$336.19M
7 Day Performance	N/A	-3.94%	-1.55%	-2.39%
1 Month Performance	N/A	-7.91%	-4.19%	-5.42%
1 Year Performance	N/A	34.20%	19.52%	13.30%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	0.7668 of 5 stars	$6.47 flat	N/A	N/A	$644.67M	$386.01M	N/A	3,008	High Trading Volume
IMNM Immunome	3.5123 of 5 stars	$22.92 +1.5%	$33.17 +44.7%	+114.2%	$2.56B	$4.02M	N/A	40	News Coverage Positive News Upcoming Earnings
TRVI Trevi Therapeutics	3.5067 of 5 stars	$18.15 +1.3%	$22.67 +24.9%	+141.2%	$2.54B	N/A	N/A	20	Positive News
TARS Tarsus Pharmaceuticals	3.7498 of 5 stars	$57.50 +2.5%	$90.67 +57.7%	+41.2%	$2.41B	$535.08M	N/A	50	Positive News
NRIX Nurix Therapeutics	2.423 of 5 stars	$23.85 +3.8%	$34.08 +42.9%	+102.4%	$2.38B	$36.77M	N/A	300	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. IMNM, TRVI, TARS, NRIX, and AGIO

How does Sinovac Biotech compare to Immunome?

Summary

How does Sinovac Biotech compare to Trevi Therapeutics?

Summary

How does Sinovac Biotech compare to Tarsus Pharmaceuticals?

Summary

How does Sinovac Biotech compare to Nurix Therapeutics?

Summary

How does Sinovac Biotech compare to Agios Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. IMNM, TRVI, TARS, NRIX, and AGIO

How does Sinovac Biotech compare to Immunome?

Does the media refer more to SVA or IMNM?

Do institutionals and insiders believe in SVA or IMNM?

Do analysts rate SVA or IMNM?

Which has higher valuation & earnings, SVA or IMNM?

Is SVA or IMNM more profitable?

Which has more risk and volatility, SVA or IMNM?

Summary

How does Sinovac Biotech compare to Trevi Therapeutics?

Is SVA or TRVI more profitable?

Do institutionals and insiders believe in SVA or TRVI?

Which has stronger earnings and valuation, SVA or TRVI?

Which has more risk and volatility, SVA or TRVI?

Does the media favor SVA or TRVI?

Do analysts recommend SVA or TRVI?

Summary

How does Sinovac Biotech compare to Tarsus Pharmaceuticals?

Which has preferable earnings & valuation, TARS or SVA?

Is TARS or SVA more profitable?

Does the media refer more to TARS or SVA?

Which has more risk and volatility, TARS or SVA?

Do analysts rate TARS or SVA?

Do insiders & institutionals hold more shares of TARS or SVA?

Summary

How does Sinovac Biotech compare to Nurix Therapeutics?

Which has higher earnings & valuation, SVA or NRIX?

Does the media favor SVA or NRIX?

Which has more volatility and risk, SVA or NRIX?

Do analysts prefer SVA or NRIX?

Is SVA or NRIX more profitable?

Summary

How does Sinovac Biotech compare to Agios Pharmaceuticals?

Is AGIO or SVA more profitable?

Does the media refer more to AGIO or SVA?

Do analysts rate AGIO or SVA?

Which has more risk and volatility, AGIO or SVA?

Which has better valuation and earnings, AGIO or SVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools